Spyre Therapeutics, Inc. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for Spyre Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 1, 2026. The reported quantity was 28,933. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F6

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F7

This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.